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Given the increased incidence of venous thromboembolism (VTE) in pediatric patients, 
which has been associated with increased survival of medically complex patients and 
increased use of invasive supportive measures, it is important to understand treatment 
options and unique aspects of anticoagulant use in children. The objective of this 
mini-review is to outline the goals of treatment, treatment options, and adverse events 
associated with the use of anticoagulants in pediatric patients with VTE.
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BACKGROUnD
Venous thromboembolism (VTE), especially hospital-acquired VTE, is increasingly recognized in 
pediatric patients. The incidence of VTE in hospitalized children has increased approximately 70% 
over a 6-year period and is thought to affect approximately 1 in every 200 hospitalized children (1). 
The rise in VTE is largely attributed to increased use of invasive support of critically ill patients, 
especially with the use of central venous access devices, which can lead to line-related VTE, and the 
improved survival of patients with complex medical conditions. Recent efforts have been made to 
better understand aspects of VTE in this patient population including risk factors for development 
of thrombosis, therapeutic outcomes, risks for recurrence, and long-term prognosis as these may 
differ from those in adult patients.
When considering treatment options in children, it is important to consider ways in which use of 
anticoagulants in pediatric patients may differ from adults. As outlined in the American College of 
Chest Physicians CHEST Guidelines for “Antithrombotic Therapy in Neonates and Children,” some 
of these important differences include (1) “epidemiology of thromboembolism in pediatric patients 
differs from that seen in adults,” (2) “hemostatic system is a dynamic, evolving entity that likely affects 
not only the frequency and natural history of thromboembolism in children but also the response 
to therapeutic agents,” (3) “distribution, binding, and clearance of antithrombotic drugs are age 
dependent,” (4) “limited vascular access reduces the ability to effectively deliver some antithrombotic 
therapies and can influence the choice of antithrombotic agent,” (5) “specific pediatric formulations 
of antithrombotic drugs are not available, making accurate, reproducible dosing difficult,” and (6) 
“dietary differences make the use of oral vitamin k antagonists particularly difficult” (2). With these 
considerations in mind, this article focuses on therapeutic options for VTE in children, which are 
important in order to optimize care and outcomes in this cohort.
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GOALS OF TReATMenT
The goals of treatment of pediatric VTE overlap with those of 
adult patients. The initial goal of anticoagulation is to halt clot 
progression. With the initiation of parenteral or enteral antico-
agulation, clot stabilization will typically occur, thus preventing 
a thrombus from expanding in length to involve additional 
venous segments, or expanding in circumferential diameter. Use 
of conventional anticoagulants will not cause clot breakdown, 
rather the body relies on its endogenous fibrinolytic system to 
dissolve the thrombus. Another important goal of treatment of 
VTE is the prevention of embolization of the thrombus from its 
original site to areas such as the lungs or central nervous system. 
When embolization does occur, it can substantially increase the 
morbidity and mortality associated with VTE (3).
With use of anticoagulation, an additional goal is prevention 
of VTE recurrence. The specific role of anticoagulation, including 
duration of therapy, is not clearly defined in regards to recurrence 
prevention. To date, no adequately powered pediatric study has 
addressed this issue; however, a current randomized controlled 
trial (RTC) is underway that has demonstrated feasibility in the 
initial pilot phase (4). The Duration of Therapy for Thrombosis 
in Children and Young Adults (Kids-DOTT) trial is a multicenter 
RTC investigating non-inferiority of a 6-week (shortened) versus 
3-month (conventional) duration of anticoagulation in patients 
aged <21 years with provoked venous thrombosis with primary 
efficacy and safety endpoints of symptomatic recurrent VTE and 
anticoagulant-related bleeding.
In medically complex patients dependent on venous access 
for life sustaining measures, including those with congenital 
heart disease requiring repeated cardiac catheterization and 
short bowel syndrome requiring long-term parenteral nutrition, 
recurrent VTE that limits adequate venous access can become a 
life-limiting condition. In this setting, use of anticoagulants for 
secondary prophylaxis is often considered to reduce the risk of 
VTE recurrence. Data regarding efficacy of specific agents and 
complications in secondary prophylaxis in an RTC are largely 
lacking in pediatrics.
A potential debilitating long-term complication of VTE is the 
development of post-thrombotic syndrome (PTS). PTS arises 
as a result of chronic venous occlusion or valvular disruption 
leading to venous hypertension. Symptoms of PTS include limb 
heaviness, swelling, pain, cramping, and ulceration. Instituting 
anticoagulation early is crucial in order to minimize risk of clot 
propagation and to encourage clot resolution, both thought to 
reduce the risks of PTS in the pediatric patient population.
TReAMenT OPTiOnS
The most common treatment options for VTE include 
unfractionated heparin (UFH), low molecular weight heparin 
(LMWH), and warfarin; other options include fondaparinux 
and the direct thrombin inhibitors (DTIs). This article will 
focus on the use of these parenteral and enteral anticoagulants; 
published data on the direct oral anticoagulants (DOACs) are 
not available at this time and thus will not be discussed in detail. 
Information regarding other modalities for management of VTE 
including thrombolytic agents and mechanical thrombolysis 
will be discussed elsewhere.
Heparins, including UFH and LMWHs, are a mainstay of 
initial VTE management in pediatric patients. UFH is often the 
first-line therapy in hospitalized pediatric patients who develop 
VTE and is used for primary prophylaxis of VTE in specific clini-
cal settings including in individuals with congenital heart disease 
undergoing certain procedures or surgical interventions. UFH 
binds to antithrombin (AT), an endogenous anticoagulant, to 
induce a conformational change that makes AT a rapid inactiva-
tor of coagulation factors especially thrombin (Factor IIa) and 
Factor Xa. Binding of AT by heparin enhances the activity of AT 
on the order of 1,000- to 4,000-fold. In children, factors such as 
reduced levels of AT and prothrombin, reduced capacity to gener-
ate thrombin, and alterations in plasma binding may affect the 
action of UFH as compared to older individuals (5, 6).
Low molecular weight heparins are fragments of heparin with 
specific activity against activated factor X and less activity versus 
thrombin. Although the efficacy of LMWHs has not been proven 
in rigorous trials, they are used widely in pediatrics. Advantages 
of LMWH over UFH include a greater and more predictable 
bioavailability due in part to dose-independent clearance, longer 
duration of anticoagulation effect allowing for less frequent 
administration, and less frequent need for monitoring, which 
is importance in pediatric patients who may have poor venous 
access, and reduced complication rates of heparin-induced 
thrombocytopenia (HIT) and osteoporosis. LMWHs include 
enoxaparin (Lovenox®) and dalteparin (Fragmin®), noting that 
most clinical data available are a pediatric cohort with enoxaparin. 
Disadvantages of these LMWHs include twice daily subcutaneous 
injections, which can be problematic for some pediatric patients.
Fondaparinux (Arixtra®) is another anticoagulant utilized 
in pediatric VTE and is a synthetic pentasaccharide that causes 
an AT-mediated selective inhibition of factor Xa; unlike the 
LMWHs, fondaparinux has nearly pure anti-factor Xa activity. 
The advantages of fondaparinux over UFH are similar to those of 
the LMWHs; however, fondaparinux has some advantages over 
LMWH including once-daily dosing and no risk for neither HIT 
nor osteoporosis.
Another class of anticoagulants utilized in pediatric VTE, 
albeit infrequently, includes the DTIs. DTIs are short-acting 
agents that are more targeted than heparin and include the 
hirudin-like molecule bivalirudin, and small-molecule inhibitor 
argatroban, which are administered by continuous intravenous 
infusion. These molecules electively bind to and inhibit thrombin 
in both circulating and clot-bound forms. As compared to UFH, 
the pharmacokinetics are more predictable and these agents are 
not dependent on AT levels, which are physiologically low in chil-
dren <6 months of age. These medications are used primarily in 
the setting of HIT, a rare but potentially life threatening condition 
mediated by IgG autoantibodies directed against platelet factor 4 
in complex with heparin that occurs after heparin exposure.
Oral agents utilized in pediatrics patients for VTE thus far are 
limited to the vitamin K antagonist (VKA) warfarin (Coumadin®) 
in the United States. Warfarin works to inhibit the synthesis of 
vitamin K-dependent coagulant proteins, which include factors 
II, VII, IX, and X. Warfarin use in pediatrics is problematic in 
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that it requires frequent monitoring, has numerous drug interac-
tions, is affected by dietary intake of Vitamin K, and has a narrow 
therapeutic range. Additionally, warfarin is only available as a 
tablet and cannot be compounded into a liquid formulation mak-
ing administration in young children difficult. VKAs in neonates 
are especially problematic due to the physiologically low levels of 
vitamin K-dependent clotting factors and the overall low vitamin 
K content of breast milk. VKA use in older children in contrast is 
often feasible with caregivers and physicians needing to balance 
the burden of frequent laboratory monitoring with dose adjust-
ments with a VKA with the need for subcutaneous injections 
utilizing LMWHs.
Direct oral anticoagulants such as the factor Xa inhibi-
tors [rivaroxaban (Xarelto®), apixaban (Eliquis®), edoxaban 
(Savaysa®)] and DTI [dabigatran (Pradaxa®)], which have been 
approved in adult patients for both treatment and prevention of 
VTE, neither have FDA-approved indications nor dosing in chil-
dren that has yet been established. Use of these agents for children 
are appealing given that they are thought to require no specific 
monitoring and overall have a risk profile in adult studies that 
is equal to, or less than, VKAs. That said, extrapolation of adult 
data to pediatric patients at this time is premature and will not 
be addressed in this article. Fortunately, there are several clinical 
trials in pediatric patients addressing dosing, adverse events, and 
ultimately comparative efficacy versus standard anticoagulation 
of DOCAs that will ultimately guide their use in pediatrics.1,2,3
To date, comparative efficacy of various anticoagulants in 
pediatric patients has largely not been studied. The REVIVE trial 
was the first multicenter, international RTC to attempt to study 
comparative efficacy of anticoagulants (7). The study was an 
open-labeled RCT of LMWH compared to heparin and couma-
din for the treatment of VTE in children that aimed to study the 
rates of recurrent VTE and death due to VTE during a 3-month 
treatment period. Unfortunately, the study was closed due to poor 
patient enrollment. Ongoing studies of the DOACs compared to 
anticoagulation currently used in pediatric patients will provide 
much needed data to guide hematologists on the specific safety 
and efficacy of these agents.
DOSinG AnD MOniTORinG
Dosing and monitoring guidelines in pediatrics have been estab-
lished, often through extrapolation from adult data (Table 1). For 
UFH, no pediatric outcome-specific studies have established a 
pediatric range for UFH; therefore, therapeutic ranges have been 
generalized from adult VTE studies. Commonly, goals for thera-
peutic anticoagulation target an anti-Xa for UFH of 0.35–0.7 U/
mL, thought to reflect to an activated partial thromboplastin time 
(aPTT) that correlates with a protamine titration of 0.2–0.4 U/mL 
1 Bayer. EINSTEIN Junior Phase III: Oral Rivaroxaban in Children with Venous 
Thrombosis (EINSTEIN Jr). Available from: www.clinicaltrials.gov.
2 Pfizer. Apixaban for the Acute Treatment of Venous Thromboembolism in Children. 
Available from: www.clinicaltrials.gov.
3 Boehringer Ingelheim. Open Label Study Comparing Efficacy and Safety of 
Dabigatran Etexilate to Standard of Care in Paediatric Patients with Venous 
Thromboembolism (VTE). Available from: www.clinicaltrials.gov.
(for purposes of this article an anti-Xa level of 0.35–0.7 will be 
assumed to reflect a aPTT of 60–85 s while acknowledging that 
this assumption may not hold true in pediatrics samples and will 
vary based on anti-Xa kit). Typically, initial UFH dosing involves 
a loading dose of 50–100 U/kg given intravenously over 10 min; 
there are little data to support this practice in pediatrics, espe-
cially in the neonatal population. Following initial bolus dose, 
maintenance dosing of 28 U/kg/h for infants (<1 year of age) and 
20 U/kg/h for children ≥1 year is utilized. Choice of monitoring 
of anti-Xa for UFH versus aPTT in children is not well established 
and differs by institution. After initiation of UFH, anti-Xa/aPTT 
is then monitored 4–6 h post bolus and every 4–6 h after a dose 
adjustment (Table 1) (2). In patients who have difficulty achiev-
ing a therapeutic aPTT, checking AT levels is recommended, 
given AT supplementation may be required if sufficiently low.
Similar to UFH, therapeutic ranges for LMWH are largely 
extrapolated from adult VTE trials and are based on measure-
ment of anti-Xa levels. For therapeutic dosing of LMWH, an 
anti-Xa of 0.5–1.0 U/mL from a sample obtained 4–6 h after a 
dose is considered in goal range; the initial anti-Xa level should 
be checked after the second or third dose is initiated. For patients 
receiving prophylactic anticoagulation to prevent recurrent VTE, 
an anti-Xa of 0.1–0.5 U/mL is typically considered goal. Dosing of 
LMWH varies by age with infants requiring often 50% increased 
dosing as compared to older children. Dosing for specific anti-
coagulants is listed in Table  1. Enoxaparin is the most widely 
utilized of the LMWHs in pediatrics and is typically initiated 
2 mg/kg/dose every 12 h in preterm neonates, in 1.7 mg/kg/dose 
every 12 h in term neonates, 1.5 mg/kg/dose every 12 h for age 
<2 months, and 1 mg/kg/dose every 12 h for age ≥2 months (8, 
9). Although enoxaparin has less activity against thrombin, in 
patients who have difficulty achieving a therapeutic anti-Xa level, 
checking AT levels to ensure that there is no significant AT defi-
ciency should be considered. Fondaparinux is monitored using 
anti-Xa levels in a similar fashion to LMWHs and is initiated at a 
dose of 0.1 mg/kg/dose once daily.
Direct thrombin inhibitor use in pediatrics is largely in the 
setting of suspected or confirmed HIT. Anticoagulation goals 
have not been well established in this population. Argatroban 
manufacturer’s dosing guidelines include pediatric usage noting 
that in critically ill pediatric patients dosing is typically started 
lower than in adult patients. In general, therapy with argatroban 
is monitored utilizing aPTT with initial monitoring preformed 
within 1–3  h from medication initiation in patients without 
hepatic impairment and approximately 2–4 h after a dose change. 
Goal aPTT is typically 1.5–3 times baseline value and avoidance 
of aPTT > 100 s. With argatroban, dosing is typically a continuous 
infusion of 0.75 and 0.2 μg/kg/min in those with hepatic impair-
ment without a bolus.4 As with argatroban, there is no estab-
lished dosing range for bivalirudin in infants and children. The 
UtilizatioN of Bivalirudin on Clots in Kids (UNBLOCK) study 
found initial bolus dosing of 0.125 mg/kg followed by an initial 
infusion of 0.125 mg/kg/h of bivalirudin demonstrated efficacy 
4 Argatroban. GlaxoSmithKline. Houston, TX. Available from: http://www. 
accessdata.fda.gov/drugsatfda_docs/label/2008/020883s014lbl.pdf.
TABLe 1 | Dosing and adjustment of anticoagulants.
Class of 
medication/drug
initial dosing Subsequent dosing Goal Dose adjustment
UFH 50–100 U/kg IV (loading dose) 28 U/kg/h (age <1 year) anti-Xa level 0.35–0.7/aPTT 60–85 s aPTT <50 s; bolus 50 U/kg, increase by 10%
aPTT <50–59 s; increase by 10%
aPTT <60–85 s; no change
aPTT <86–95 s; decrease by 10%
aPTT <96–120 s; hold dose × 30 min, decrease by 10%




2 mg/kg/dose SC q 12 h (preterm neonates)
1.7 mg/kg/dose SC q 12 (term neonates)
1.5 mg/kg/dose SC q 12 h (age <2 months)
1 mg/kg/dose SC q 12 (age ≥2 months)
anti-Xa level 0.5–1 (treatment) anti-Xa <0.35; increase dose by 25%
anti-Xa 0.35–0.49; increase dose by 10%
anti-Xa 0.5–1; no change
anti-Xa 1.1–1.5; decrease dose by 20%
anti-Xa 1.6–2; hold for 3 h and decrease dose by 30%
anti-Xa >2; hold until anti-Xa 0.5–1 then decrease dose by 40%
Prophylactic dosing
0.75 mg/kg/dose SC q 12 h (age <2 months)
0.5 mg/kg/dose SC q 12 h (age <2 months)
anti-Xa level 0.1–0.5 (prophylaxis) anti–Xa <0.1; increase dose by 25%
anti-Xa 0.1–0.5; no change
anti-Xa 0.51–1; decrease dose by 20%
anti–Xa >1; decrease dose by 30%
Dalteparin 129 ± 43 U/kg/dose SC q 24 h
Fondaparinux Treatment dosing
0.1 mg/kg SC q 24 h anti-Xa level 0.5–1 (treatment) anti-Xa <0.3; increase dose by 0.03 mg/kg
anti-Xa 0.3–0.49; increase dose by 0.01 mg/kg
anti-Xa 0.5–1; no change
anti-Xa 1.1–1.2; decrease dose by 0.01 mg/kg
anti-Xa >1.2; decrease dose by 0.03 mg/kg
Prophylactic dosing
0.05 mg/kg SC q 24 h anti-Xa level 0.1–0.5 (prophylaxis) anti-Xa <0.1; increase dose by 25%
anti-Xa 0.1–0.5; no change
anti-Xa 0.51–1; decrease dose by 20%
anti-Xa >1; decrease dose by 30%
VKA
Warfarin 0.1–0.2 mg/kg (max dose 5 mg) PO q 24 h INR 2–3 Day 2–4 consider dose adjustment in day 2–4
INR 1.1–1.3; repeat initial dosing
INR 1.4–3.0; give 50% of loading dose
INR 3.1–3.5; give by 25% of loading dose
INR >3.5; hold until INR <3.5 then restart at 50% dosing
Maintenance
INR 1.1–1.4; increase by 20%
INR 1.5–1.9; increase by 10%
INR 2.0–3.0; no change
INR 3.1–3.5; decrease by 10%
INR >3.5; hold until INR <3.5; restart at 20% decreased dosing
DTI
Argatroban 0.75 μg/kg/min IV
0.2 μg/kg/min IV (hepatic impairment)
aPTT 1.5–2.5× baseline
Bivalirudin 0.125–0.25 mg/kg (loading dose) IV 0.125–0.2 mg/kg/h aPTT 1.5–3× baseline
UFH, unfractionated heparin; LMWH, low molecular weight heparin; VKA, vitamin K antagonist; DTI, direct thrombin inhibitor; IV, intravenously; SC, subcutaneously; PO, orally; aPTT, activated partial thromboplastin time; INR, 
















February 2017 | Volum
e 5 | A
rticle 26
TABLe 2 | Anticoagulant reversal options for bleeding patients and over dosages.
Class of medication/drug Reversal strategy Time since last dose of anticoagulant 
medication
Dosage of reversal agent




1 mg protamine per 100 U of heparin
0.5–0.75 mg protamine per 100 U of heparin
0.375–0.5 mg protamine per 100 U of heparin
0.25–0.375 mg protamine per 100 U of heparin
Low molecular weight heparin
Enoxaparin Protamine ≤8 h
>8 h
1 mg protamine per 1 mg enoxaparin
0.5 mg protamine per 1 mg enoxaparin
Dalteparin Protamine N/A
If bleeding 2–4 h after first protamine dose
1 mg protamine per 100 U of dalteparin
0.5 mg protamine per 100 U of dalteparin




N/A; if international normalized ratios  
>10 and no bleeding
N/A; if VKA-associated major bleeding occurs
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and reassuring safety in a cohort of pediatric patients with acute 
VTE (10). Historically, monitoring of bivalirudin utilizing aPTT 
with a goal of 1.5–2.5× the baseline aPTT has been suggested; 
however, the UNBLOCK study demonstrated poor correlation 
between aPTT and plasma bivalirudin concentration suggesting 
limited utility of aPTT monitoring with this drug.
As with adult patients utilizing VKAs, target international 
normalized ratios (INRs) for anticoagulation are typically 2.0–3.0; 
to date, there have been no clinical trials to address optimal INRs 
for a pediatric cohort. In patients requiring anticoagulation for 
mechanical heart valves, a target INR of 2.5–3.5 mimic target 
INRs was fixed for adult patients. Warfarin is begun at a dose 
of 0.1 mg/kg, or alternatively with a loading dose of 0.2 mg/kg 
(maximum dose of 5  mg), with daily monitoring and dose 
adjustment in the first 5 days (Table 1) followed by monitoring 
of maintenance dosing (2). During the first 5 days of VKA use, 
and until the INR is at least 2.0 for two consecutive days, a heparin 
product should be utilized. This “bridging anticoagulant” is used 
to prevent against warfarin-induced skin necrosis, which occurs 
due to a relative decrease of vitamin K-dependent endogenous 
anticoagulants prior to a decrease of endogenous procoagulants. 
Repeat INR testing needs to be considered with changes to con-
comitant medication use or medical illness.
DURATiOn OF THeRAPY
Duration of therapy for VTE in pediatric patients has been 
less well defined and is largely extrapolated from adult data. A 
recommendation of a 3-month course of anticoagulation for 
pediatric patients with provoked VTE has been based on the 
results of clinical trials in adults with a shorter, 6-week course, of 
anticoagulation considered in certain pediatric patient popula-
tions; these recommendations have not been based on evidence 
from pediatric trials. The American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines provides guidance 
for duration of therapy for pediatric patients with VTE in various 
settings, including consideration of longer duration of therapy 
in the setting of serious, unprovoked thrombosis and is largely 
used in pediatric practice to guide duration therapy (2). Notably, 
the pediatric recommendations from the CHEST Guidelines are 
largely based on expert opinion, case series, and relatively small 
studies rather than large RTCs, which have guided treatment 
recommendations in adult population.
ADveRSe evenTS
With the use of any anticoagulant, the primary adverse event 
of therapy is bleeding. Given the lack of comparative efficacy 
studies in pediatrics, no adequately powered study has compared 
bleeding rates of one drug compared to another for treatment 
of UFH-related bleeding, given the short half-life of the medica-
tion, discontinuation of the medication is often sufficient. In the 
event of more severe bleeding or when immediate reversal may 
be needed preoperatively, use of protamine sulfate will rapidly 
neutralize UFH; guidelines for reversal are available (Table 2) (2). 
Although limited data are available for LMWH-related bleeding 
in the setting of overdosage, use of protamine can be considered 
(Table  2).5,6 It is important to note that the anti-Xa activity is 
never completely neutralized; with enoxaparin a maximum of 
60% and dalteparin a maximum of 60–75%, of the anti-Xa activ-
ity is neutralized.
Adverse events such as HIT are relatively rare in the pediatric 
population; however, this poses a potentially life threatening 
complication and narrows options for VTE treatment. Rates of 
HIT in pediatrics range from 0 to 3.7% (11). In adult patients, the 
pretest clinical scoring system commonly used known as the 4T 
score is not applicable in pediatric patients given the overall rarity 
of HIT in children versus adults.
For those individuals who require long-term preventative 
anticoagulation, other considerations need to be made such as 
the risk of osteoporosis with heparins. In adult patients, exposure 
5 Lovenox. Sanofi-Aventis. Bridgewater, NJ. Available from: http://products.sanofi.
us/lovenox/lovenox.html#section-12.
6 Dalteparin. Pfizer. New York, NY. Available from: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2015/020287s062lbl.pdf.
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to LMWH beyond 3–6 months may adversely affect bone mineral 
density; large epidemiologic studies of osteoporosis in pediatric 
patients with long-term heparin/LMWH exposure have not been 
conducted, but given the relationship between heparin use and 
osteoporosis in adults, this should likely be avoided in pediatric 
patients as well (12, 13).
COnCLUSiOn
Given the increasing incidence of VTE in pediatric patients, it 
is crucial to understand treatment options for VTE including 
ways in which the hemostatic system and anticoagulant dosing 
and monitoring are different in this cohort as compared to adult 
patients. Notably, there is a lack of robust research aimed at 
addressing dosing, monitoring, safety, comparative efficacy, and 
duration of therapy to guide optimal care in pediatric patients, 
which offers areas for research focus for the future.
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